Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.36 |
| ▸ | HTR2C | P28335 | 9/20 | 0.36 |
| ▸ | HTR2B | P41595 | 8/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105041 | 0.81 | HTR2C (0.60) | HTR2AHTR2CHTR2B | |
| SCHEMBL18577020 | 0.69 | PNMT (0.52) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL30098006 | 0.69 | PNMT (0.52) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL13673173 | 0.69 | HTR2A (0.42) | HTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL7638137 | 0.68 | PNMT (0.50) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL29051809 | 0.68 | DRD2 (0.49) | HTR2AHTR2CHTR2B | |
| SCHEMBL30468465 | 0.68 | ADRA2A (0.49) | HTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL6666115 | 0.67 | RXRA (0.48) | BCHECES1BACE1 | |
| SCHEMBL18537161 | 0.65 | SIGMAR1 (0.43) | HTR2AHTR2CADRA2A | |
| SCHEMBL23813190 | 0.65 | CRBN (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846906-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8575149-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8546378-B2 | 5HT2C receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546379-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130217677-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130012495-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012498-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20120252786-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252788-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-8273734-B1 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8207158-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120135982-A1 | 5HT2c RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252786-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | HTR2C, HTR5A, HTR2A | HTR2A 3/4885HTR2C 1/4885HTR2B 11/4885 |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20130012495-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20130217677-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | HTR2C, HTR5A, HTR2A | HTR2A 3/4885HTR2C 1/4885HTR2B 11/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20120252788-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20120135982-A1 | 5HT2c RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20130012498-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2A 2/4885HTR2C 1/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.